Regarding SLE, a meta-analysis concluded that, although statins did not have a direct effect on lupus activity, they did result in CRP reduction, thus achieving indirect beneficial effects on patients while also decreasing the effect of the well-known accelerated atherosclerosis in patients with SLE [22]. Here, CRP is linked to systemic lupus erythematosus.